Need a Health professional?

Shreyaansh Lifesciences, Jaipur. India

Trabectedin Injection 1 mg
Trabectedin injection is used to treat liposarcoma (a cancer that begins in fat cells) or leiomyosarcoma (a cancer that begins in smooth muscle tissue) that has spread to other parts of the body and cannot be treated with surgery in people who have already been treated with certain chemotherapy medications

Trabectedin Injection is approved for use in the European Union, Russia, South Korea and the United States. The European Commission and the U.S. Food and Drug Administration (FDA) granted orphan drug status to trabectedin for soft-tissue sarcomas and ovarian cancer.

 

 

 

 

 

 

 

 

 

 

Trabectedin Injection price, Available in Delhi, India, U.K.

Trabectedin Injection

  • Innovator Brand Name – Yondelis
  • Generic Brand Available – Trabec
  • API – Trabectedin
  • Packaging – Single-dose vial
  • Strength – 1mg
  • Manufacturer Name – Natco Pharma Ltd.

What is trabectedin used for?

Trabectedin Injection is an alkylating medication used to treat patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have taken an earlier anthracycline-containing regimen. 

Disclaimer

All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.

Get Access To Trabectedin Injection 1 mg

Shreyaansh Lifesciences, Jaipur. India

Shreyaansh Lifesciences is registered in Jaipur, India. Registration Number : 08AEEFS9350K1ZI under GST Act. 
Branch Offices in India : Jaipur | New Delhi

SF-72-73 2ND FLOOR, Jaipur Electronic Market, Ridhi Sidhi Choraha, Jaipur, Rajasthan, 302018.

+91 99292 77766

Facts of Medicines

Trabectedin Injection 1 mg

HOW SUPPLIED/STORAGE AND HANDLING:

Store Trabectedin vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Trabectedin is a cytotoxic drug. Follow applicable special handling and disposal procedures.

SIDE EFFECTS

Commonly reported trabectedin side effects include: constipation, nausea, fatigue, decreased appetite, peripheral edema, vomiting, diarrhea, dyspnea, headache.

TRABECTEDIN DOSAGE

The standard dose of Trabectedin is 1.5 mg/m2 which should be administered as an intravenous infusion over 24 hours through a central venous line every 3 weeks or 21 days, until the disease is progressive or unacceptable toxicity occurred, in patients with normal bilirubin and AST or ALT less than or equal to 2.5 times the upper limit of normal.

WARNINGS AND PRECAUTIONS

  • Administer the dexamethasone 20 mg intravenously 30 minutes before each dose of Trabectedin.
  • Trabectedin 1 mg is contraindicated in patients with severe hypersensitivity, including anaphylaxis, to trabectedin.
  • Neutrophil count needs to be assessed before the administration of each dose of Trabectedin and then periodically throughout the therapy.
  • Assess LFTs before each administration of trabectedin injection. Manage the elevated LFTs with interruption of therapy, dose reduction, or permanent discontinuation based on severity and duration of LFT abnormality.
  • Assess left ventricular ejection fraction (LVEF) by echocardiogram or MUGA (Multigated Acquisition) scan prior to beginning of trabectedin and at 2-3 month intervals thereafter until the therapy is discontinued.
  • Based on its mechanism of action, trabectedin injection can cause fetal harm in cases administered to a pregnant woman.
  • Due to potential for severe adverse events from trabectedin in breastfed infants, nursing women are advised to interrupt nursing while on trabectedin treatment.

FAQs – Medicine Questions

Trabectedin Injection 1 mg
What is Trabectedin?

Trabectedin specifically is an antitumor chemo medicine aimed to treat advanced soft-tissue sarcoma and ovarian cancer.

How should Trabectedin 0.25 mg be administered?

Trabectedin 0.25 mg should be administered as an intravenous infusion.

Who should not receive Trabectedin?

You will not be given trabectedin if you have had a severe allergic reaction to Trabectedin.

Where can I buy Trabectedin Injection injection?

You can buy Trabectedin Injectionfrom any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

The buyer should check the existing law in their home country before importing the product.

What is the procedure to buy Trabectedin Injection?

Patients can simply fill the order form or can send mail at info@treatmentoptions4u.com. Patients can also send WhatsApp messages to +91 98738 10020. We will reply ASAP with the details of the Trabectedin Injection price as well as procurement procedure.

Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

What should I avoid while receiving Trabectedin?

Patients are advised to avoid grapefruit as well as grapefruit juice while on therapy with Trabectedin.

NEWS / UPDATES

  1. Janssen Pharmaceutical Companies, [Revised on Jun 2020] [Accessed on 2nd Jun 2021], https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/YONDELIS-pi.pdf
  2. Pharma Mar, Electronic Medicines Compendium (EMC), [Revised on Jul 2020] [Accessed on 2nd Jun 2021], https://www.medicines.org.uk/emc/files/pil.6164.pdf
  3. Uboldi et al., Mechanism of action of trabectedin in desmoplastic small round cell tumor cells, BMC Cancer, 2017, [Accessed on 2nd Jun 2021], https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-017-3091-1.pdf
  4. Demetri et al., Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial, Journal of Clinical Oncology, 2016, 34(8), [Accessed on 2nd Jun 2021], https://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.62.4734